[{"indications": "Indications\u00a0management of cystic fibrosis patients with a forced vital capacity\r\n(FVC) of greater than 40% of predicted to improve pulmonary function", "name": "DORNASE ALFA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "3 Respiratory system", "3.7 Mucolytics", "Dornase alfa", "DORNASE ALFA"], "side-effects": "Side-effects\u00a0rarely dyspepsia, chest pain,\r\ndysphonia, dyspnoea, pharyngitis, laryngitis, pyrexia, conjunctivitis,\r\nrhinitis, rash, urticaria", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/20298.htm", "doses": ["adult and child over 5 years, by inhalation of nebulised\r\nsolution (by jet nebuliser), 2500\u00a0units (2.5\u00a0mg) once daily\r\n(patients over 21 years may benefit from twice daily dosage)"], "pregnancy": "Pregnancy\u00a0no evidence of teratogenicity; manufacturer advises\r\nuse only if potential benefit outweighs risk"}]